Literature DB >> 14718578

Role of neuronal KATP channels and extraneuronal monoamine transporter on norepinephrine overflow in a model of myocardial low flow ischemia.

Christof Burgdorf1, Andreas Dendorfer, Thomas Kurz, Edgar Schömig, Ines Stölting, Frank Schütte, Gert Richardt.   

Abstract

Global myocardial low flow ischemia results in an uniform suppression of norepinephrine (NE) overflow from the heart. We hypothesized that opening of neuronal ATP-sensitive potassium (K(ATP)) channels as well as activation of the extraneuronal monoamine transporter (EMT) mediates attenuation of NE overflow during low flow ischemia. Isolated rat hearts were subjected to low coronary flow of 0.4 ml min(-1). Release of endogenous NE was induced by electrical field stimulation. EMT activity was measured as the transport rate of the substrate N-[methyl-3H]4-phenylpyridinium ([3H]MPP+). NE overflow decreased by 57 +/- 2% within 120 min of low flow. Five minutes of reperfusion at normal flow (8 ml min(-1)) restored NE overflow to baseline. K(ATP) channel blockade with glibenclamide as well as EMT blockade with corticosterone increased NE overflow 1.5- and 2-fold at 120 min of low flow, whereas neither drug affected NE overflow in the absence of flow reduction. At normal flow, K(ATP) channel opening with cromakalim suppressed NE overflow, both in the presence and absence of EMT blockade (14 +/- 4 and 9 +/- 1%). However, cromakalim had no effect on EMT activity as indicated by an unaffected [3H]MPP+ overflow. In conclusion, activation of both K(ATP) channels and EMT mediate suppression of NE overflow during low flow ischemia. K(ATP) channels impair NE release directly at presynaptic nerve endings, whereas EMT increases NE elimination in a manner independent of K(ATP) channels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718578     DOI: 10.1124/jpet.103.059832

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Tempol attenuates the exercise pressor reflex independently of neutralizing reactive oxygen species in femoral artery ligated rats.

Authors:  Jennifer L McCord; Hirotsugu Tsuchimochi; Katsuya Yamauchi; Anna Leal; Marc P Kaufman
Journal:  J Appl Physiol (1985)       Date:  2011-07-07

2.  Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients with acute decompensated heart failure.

Authors:  Shu Kasama; Takuji Toyama; Ryuichi Funada; Noriaki Takama; Norimichi Koitabashi; Shuichi Ichikawa; Yasuyuki Suzuki; Naoya Matsumoto; Yuichi Sato; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-30       Impact factor: 9.236

3.  Inhibition of KATP channels in the rat tail artery by neurally released noradrenaline acting on postjunctional alpha2-adrenoceptors.

Authors:  Joy H Tan; Amr Al Abed; James A Brock
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

4.  Vascular-dependent effects of elevated glucose on postganglionic sympathetic neurons.

Authors:  Deborah H Damon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

5.  Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching.

Authors:  Shu Kasama; Takuji Toyama; Toshiya Iwasaki; Hiroyuki Sumino; Hisao Kumakura; Kazutomo Minami; Shuichi Ichikawa; Naoya Matsumoto; Yuichi Sato; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-28       Impact factor: 9.236

6.  Effects of statin therapy on cardiac sympathetic nerve activity and left ventricular remodeling in patients with chronic heart failure: a propensity score-matched analysis.

Authors:  Hirokazu Sano; Shu Kasama; Shinichiro Fujimoto; Takuji Toyama; Noriaki Takama; Norimichi Koitabashi; Shuichi Ichikawa; Yasuyuki Suzuki; Naoya Matsumoto; Yuichi Sato; Masahiko Kurabayashi
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.